VKTX / Viking Therapeutics joins weight loss drug bandwagon as trial data impresses

Viking Therapeutics is looking to profit from the expanding market for obesity drugs. The company's two leading candidates are currently in phase 2 cl more_horizontal

Viking Therapeutics (NASDAQ: VKTX ) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. more_horizontal

Viking Therapeutics (NASDAQ:VKTX) shares shot up 12% in overnight US trading as the drug developer revealed more impressive trial data from a treatmen more_horizontal

Viking Therapeutics Inc. VKTX, -0.37% shares rose in the extended session Tuesday after the biotech drug developer said data from an early stage clini more_horizontal

After positive mid-stage data, Eli Lilly seems to have a chance at achieving best-in-class status in the valuable weight loss market. Viking's shares more_horizontal

A top competitor announced plans to move forward with a late-stage weight loss candidate today. Viking's weight-loss candidate is several years behind more_horizontal

Viking Therapeutics has a few drugs that have the potential to generate billions in revenue. The problem is that they are in early-stage trials, so th more_horizontal

Viking Therapeutics is a biotech with multiple potential blockbuster drugs in its portfolio. Encouraging trial results have made investors bullish abo more_horizontal